Protein A-Duocarmycin ADC (CAT#: ADC-AA-055)

A: The Protein A-Duocarmycin ADC is composed of Protein A conjugated via a linker to Duocarmycin. Duocarmycin is a cytotoxic agent that targets certain cancers through immune recognition and is delivered into cancer cells via receptor-mediated endocytosis, leading to DNA damage and subsequent cell death.

A: Duocarmycin functions by binding to DNA within the cancer cells, causing DNA damage that leads to cell death. This mechanism is specifically activated after the ADC is internalized into the target cells, making Duocarmycin a potent agent for targeted cancer therapy.

A: Protein A in this ADC binds to the Fc region of antibodies, facilitating the targeting of Duocarmycin to specific cancer cells. This interaction allows the ADC to utilize immune recognition, leading to the receptor-mediated endocytosis of Duocarmycin into the cancer cells, where it exerts its cytotoxic effects.

A: This ADC is considered economical because it can be used without the need for a primary antibody, reducing the costs associated with pre-screening monoclonal antibodies. Researchers can test the cytotoxic potential of Duocarmycin without the need to develop specific monoclonal antibodies, streamlining the screening process.

A: Yes, Creative Biolabs offers customization services for the Protein A-Duocarmycin ADC. Researchers can request modifications to the linker, conjugation process, or specific components to suit their experimental needs, allowing for tailored solutions that align with their research objectives.

A: The Protein A-Duocarmycin ADC is designed to target cancer cells that express Fc receptor-binding antibodies. It is particularly effective in cancers where immune recognition through the Fc region is a viable targeting strategy. Researchers should evaluate the expression levels of Fc receptors in their cancer model to determine the suitability of this ADC for their studies.